Efficacy and safety of dapagliflozin were similar in patients with type 2 DM and atherosclerotic CVD, regardless of PAD.

Efficacy and safety of dapagliflozin were similar in patients with type 2 DM and atherosclerotic CVD, regardless of PAD.
Ann Intern Med. 2021 Jan 05;:
Authors: Hao Q, Guyatt G
Abstract
SOURCE CITATION: Bonaca MP, Wiviott SD, Zelniker TA, et al. Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58. Circulation. 2020;142:734-47. 32795086.
PMID: 33395336 [PubMed - as supplied by publisher]

Source: Annals of Internal Medicine - January 5, 2021 Category: Internal Medicine Authors: Hao Q, Guyatt G Tags: Ann Intern Med Source Type: research